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Abstract
Introduction: Cancer is often suggested to result from development gone awry. Links between normal embryonic
development and cancer biology have been postulated, but no defined genetic basis has been established. We
recently published the first transcriptomic analysis of embryonic mammary cell populations. Embryonic mammary
epithelial cells are an immature progenitor cell population, lacking differentiation markers, which is reflected in
their very distinct genetic profiles when compared with those of their postnatal descendents.
Methods: We defined an embryonic mammary epithelial signature that incorporates the most highly expressed
genes from embryonic mammary epithelium when compared with the postnatal mammary epithelial cells. We
looked for activation of the embryonic mammary epithelial signature in mouse mammary tumors that formed in
mice in which Brca1 had been conditionally deleted from the mammary epithelium and in human breast cancers
to determine whether any genetic links exist between embryonic mammary cells and breast cancers.
Results: Small subsets of the embryonic mammary epithelial signature were consistently activated in mouse
Brca1-/- tumors and human basal-like breast cancers, which encoded predominantly transcriptional regulators, cell-
cycle, and actin cytoskeleton components. Other embryonic gene subsets were found activated in non-basal-like
tumor subtypes and repressed in basal-like tumors, including regulators of neuronal differentiation, transcription,
and cell biosynthesis. Several embryonic genes showed significant upregulation in estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and/or grade 3 breast cancers. Among them, the transcription factor, SOX11, a
progenitor cell and lineage regulator of nonmammary cell types, is found highly expressed in some Brca1-/-
mammary tumors. By using RNA interference to silence SOX11 expression in breast cancer cells, we found evidence
that SOX11 regulates breast cancer cell proliferation and cell survival.
Conclusions: Specific subsets of embryonic mammary genes, rather than the entire embryonic development
transcriptomic program, are activated in tumorigenesis. Genes involved in embryonic mammary development are
consistently upregulated in some breast cancers and warrant further investigation, potentially in drug-discovery
research endeavors.
Introduction
The notion that some cancers may arise because of the
reactivation of embryonic developmental programs was
first proposed in the 19th century. Among the propo-
nents of this idea was Rudolf Virchow, who recognized
elements of embryonic development in cancers. Virchow
coined the term “teratoma” to describe tumors containing
differentiated elements of the three embryonic germ
layers and also suggested that cancers arise from embryo-
like cells [1]. Lobstein and Cohnheim [2] also noted simi-
larities between embryogenesis and the biology of cancer
cells and put forward the hypothesis that tumorigenesis
recapitulates aspects of development [2]. During organ
formation, cells proliferate, migrate, and invade into adja-
cent tissues to produce highly organized tissues, and
these same cellular processes are used during carcinogen-
esis, which results in the formation of relatively organized
populations of abnormal cells, which comprise tumors.
Therefore, it has been suggested that some tumors arise
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from reactivation of embryonic developmental programs
in postnatal tissues.
Two of the most common breast cancer-driver muta-
tions, which confer clonal selective advantage on cancer
cells and are causally implicated in oncogenesis, are
found in GATA3 and TBX3, which are genes that have
been shown to be required for embryonic mammary
development [3-5]. Many other signaling pathways have
also been implicated in both embryonic mammary mor-
phogenesis and carcinogenesis, providing support for
the contention that neoplastic and immature tissues
share important similarities and that organ development
and primary tumor formation are likely to be under-
pinned by common mechanisms [6]. Newly identified
cancer stem cells in skin, gut, and brain are very similar
to healthy stem cells responsible for growing and renew-
ing tissue in the body, highlighting the need for further
understanding of the normal mammary progenitor cells
and their potential links to cancer, as tumors may
develop from progenitor-like cells from diverse stages of
cellular differentiation [7-9].
Recently we completed a transcriptomic analysis of
embryonic mouse mammary primordial cells, the first
such study of separated embryonic mammary epithelial
and mammary mesenchymal cell populations [10]. These
two cell populations interact in a complex, reciprocal
manner as the mammary primordium forms during
embryogenesis. Recent data from cell-lineage tracing stu-
dies suggest that embryonic mammary cells are the only
cell populations that are truly multipotent in vivo [11].
Embryonic mammary epithelial cells are an immature cell
population, lacking differentiation markers, which is
reflected in their very distinct genetic profiles when com-
pared with those of their postnatal descendents [10].
In this study, we explored the hypothesis that reactiva-
tion of embryonic developmental programs in mature
breast cells promotes tumor formation. We defined an
embryonic mammary signature to incorporate the most
highly expressed genes from the embryonic epithelium
during organ formation when compared with the postna-
tal mammary epithelial cells and compared them with
gene signatures of breast cancers. We found reactivation
of small modules of embryonic mammary epithelial
genes within mouse Brca1-/- tumors and human basal-
like/triple-negative breast cancers. Many embryonic
genes are activated across breast cancer datasets, and sev-
eral are linked to clinical parameters, including hormone-
receptor expression, subtype, and grade. We found that
embryonic mammary signature activation in breast can-
cer samples is predictive of breast cancer patient out-
come, suggesting clinical relevance. Our studies therefore
provide new insights into the association of embryonic
signature activation with clinical features of some breast
cancers.
Materials and methods
Data analysis
Transcriptome analysis on normal mammary populations
and tumor RNA profiled with Affymetrix 430 2.0 mouse
gene-expression chips was as described [10,12,13]. The
microarray data are available in ArrayExpress with acces-
sion numbers E-TABM-1099, E-TABM-683, E-TABM-
684, and E-TABM-997. Raw Affymetrix.CEL files were
normalized and summarized by robust multiarray analysis
(RMA) by using the Affy package from BioConductor
[14]. Probe sets were used for a multiclass Significance
Analysis of Microarrays (SAM) by using a local false-dis-
covery rate of 5% to determine whether their mean
expression was different across the three mammary
epithelial cell (MEC) subpopulations and three embryonic
mammary populations described [10,13]. Probes are con-
sidered embryonic-enriched when they have a mean rela-
tive abundance of 10-fold or more when compared with
the postnatal mammary epithelial samples.
With 799 probe sets shown to distinguish robustly
between embryonic mammary epithelium and postnatal
mammary cells, normal and tumor samples were clustered
by using a Ward algorithm based on Pearson correlation
distance. Human orthologues for 689 genes encoded by
the 799-probe set were used to cluster human breast can-
cers in three datasets [15-17] based on Ward clustering
with correlation distance. Breast cancer subtypes in the
Natrajan [16] and NKI295 [15] datasets were as defined by
the research version of PAM50 classification [18]; PAM50
from Parker et al. [17] was used to describe subtypes in
the UNC337 dataset [17]. The 70-gene prognosis signature
was used to classify tumors into poor or good prognosis
on the basis of their risk of developing distant metastases
within 5 years [15,19].
We tested for presence of clusters and observed hier-
archic clustering with two clusters to be the most suitable
for our dataset. The agglomerative method of Ward hier-
archic clustering, as implemented in the R-package
pvclust [20], was used for subsequent analysis. Para-
meters were set to 10,000 bootstrap replicates, with rela-
tive sample sizes set from 0.5 to 1.4, incrementing in
steps of 0.1 to determine AU (approximately unbiased) P
values. Hypergeometric statistical analysis was used to
demonstrate that enrichment of embryonic gene activa-
tion in mouse tumor and breast cancer datasets was
significant.
We used proliferation signatures defined by Ben-Por-
ath et al. [21] to designate tumor-associated embryonic
genes as proliferative or not. Two additional prolifera-
tion signatures, defined, by Desmedt et al. [22] and
Ghazoui et al. [23], provided a list of additional genes to
exclude. For Spearman correlation, a cut-off was used to
exclude all genes with an absolute correlation > 0.5 with
proliferation genes.
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From the embryonic and postnatal mammary gene sig-
natures, centroids were defined for 37 genes comprising
the nonproliferative embryonic gene signature. Centroid
correlation was performed with the NKI295 dataset by
using Spearman correlation. The nearest centroid was
recorded for every sample, and those with correlation of <
0.1 were assigned to no correlation, whereas those with a
correlation ≥ 0.1 were classified as “embryonic.” Kaplan-
Meier analysis and multivariate Cox proportional hazard
regression analysis were carried out with the R survival
package. The nonproliferative embryonic gene signature
and tumor annotations were tested in models containing
various combinations of tumor size, differentiation status,
lymph node positivity, ER status, and 70-gene signature, as
indicated.
Pathway and network analysis
Pathway analysis was performed by using functional
annotation cluster analysis by using DAVID [24]. An
interaction network was generated within ROCK by
using genes of interest and visualized by using ROCK-
scape [25]. Initially, only interactions between selected
genes were allowed; this was then extended by allowing
one joining gene between two selected genes to form
interactions where the genes were not interacting in the
first phase.
Statistical analysis of embryonic mammary genes in
tumors
For expression fold-change, genes were submitted in the
ROCK resource [25] to identify significant changes in
expression between specific groups of tumors. Only stu-
dies in which samples were run on the same chip and nor-
malized in the same manner were included. An average
fold-change of twofold or more (up or down) was consid-
ered a significant fold-change. Results were also verified by
using (SAM) analysis tool in ROCK to determine signifi-
cant changes of expression in subtypes, tumor type, and
grade classification. Molecular subtypes were defined by
PAM50 [17].
For survival curves, genes with significant expression
changes were subjected to Kaplan-Meier plot survival cal-
culation within the ROCK resource. Significant impact on
survival was assumed if the c2 P value was < 0.05, or its
associated log2 rank P value was < 0.05.
Sample collection
All animal work was carried out under UK Home Office
project and personal licenses after local ethical approval
from The Institute of Cancer Research Ethics Committee
and in accordance with local and national guidelines.
Embryonic day 12.5 (E12.5) mammary primordia were
manually microdissected, and tissue separations were
performed as previously described [10].
Quantitative real-time polymerase chain reaction
Total RNA was extracted from purified populations of two
to three independent biologic replicates by using Qiagen
RNeasy Micro Plus kit (Qiagen, Hilden, Germany). cDNA
synthesis of RNA was carried out by using Quantitect
Reverse Transcription kit (Qiagen, Hilden, Germany) and
run with TaqMan Array Assay-on-Demand probes
(Applied Biosystems, Life Technologies Corporation,
Carlsbad, CA, USA). Results were analyzed by using the
Δ-ΔCt method normalized to Actb. Total RNA from tumor
and mammary samples were reverse transcribed and line-
arly amplified by using the Ovation Amplification System
V2 kit (NuGEN Technologies, San Carlos, CA, USA), as
described previously, before Quantitative real-time poly-
merase chain reaction (qRT-PCR) analysis [10]. The
expressions of SOX11 in BT474 and BT549 cells were ana-
lyzed with qRT-PCR by using TaqMan Gene Expression
Assay for SOX11, Hs00846583_s1 (Applied Biosystems,
Life Technologies Corporation, Carlsbad, CA, USA) com-
bined with FAM and normalized against b-actin,
Hs99999903_m1, combined with VIC.
Immunohistochemistry and whole-mount
immunofluorescence
Methods were as previously described [10,26]. Antibodies
are listed in Additional file 1A; Sox11 guinea pig anti-
serum is described [27]; and the specificity of this antibody
was previously demonstrated [28]. Transverse cryosections
from the forelimb region of Sox11-/- embryos were used to
demonstrate the specificity of the SOX11 mouse monoclo-
nal antibody MRQ-58 from Cell Marque (Rocklin, CA,
USA) in mouse tissue. Negative controls were performed
for all antibodies by the omission of primary antibody.
Expression at other sites (embryonic brain or skin) was
used for positive controls. Representative micrographs of
controls are shown in Additional file 1B, C.
SOX11 knockdown in breast cancer cells
BT474 and BT549 cells were transfected with 80 pmol of
each SOX11 siRNA (siGENOME SMARTpool and four
individual siRNAs), control nontargeting siRNA or Cyclo-
philin control siRNA (Thermo Scientific, Waltham, MA,
USA) by using Lipofectamine 2000 (Invitrogen, Life Tech-
nologies Corporation, Carlsbad, CA, USA) in Opti-MEM
(Gibco, Life Technologies Corporation, Carlsbad, CA,
USA) media according to the manufacturer’s instructions
for 6 hours in a six-well plate, and then incubated with
DMEM supplemented with 10% fetal bovine serum.
BT474 cells were lysed with RIPA buffer 72 hours after
transfection and subjected to immunoblotting, as pre-
viously described [29]. SOX11 expression was detected
by using a rabbit monoclonal antibody (Epitomics, Bur-
lingame, CA, USA, clone EPR8192); caspase-3 (R&D Sys-
tems, Minneapolis, MN, USA) and cleaved caspase-3
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(Cell Signaling Technology, Danvers, MA, USA) were
detected by using mouse monoclonal and rabbit polyclo-
nal antibodies.
SOX11 overexpression
The 1 × 106 BT549 cells were transfected with 3 μg of
either pCMV6-AC-GFP plasmid containing the sequence
for a fusion protein between SOX11 and GFP (RG220681,
Origene Rockville, MD, USA) or a control plasmid con-
taining GFP, pIRES2-EGFP (Clontech, Mountain View,
CA, USA), by nucleoporation by using the Amaxa Cell
Line Nucleofector kit V (Lonza, Basel, Switzerland) with
the T-024 program. The transfection efficiency was evalu-
ated with flow cytometry.
Cell-viability assays
At 48 hours after transfection, 3,000 BT474 cells or 1,000
BT549 cells were plated per well of a 96-well plate. Cell-
growth rates were assessed 24, 48, and 72 hours later by
incubating for 2 hours with PrestoBlue Cell Viability
Reagent (Life Technologies, Carlsbad, CA, USA). The
absorbance obtained at each time point was normalized to
the absorbance at 0 hours. Statistical significance was
determined by using a two-way ANOVA test followed by
a Bonferroni post hoc test. The results at 72 hours are pre-
sented as the percentage of growth relative to the popula-
tion transfected with the nontargeting siRNA. Statistical
significance was determined by using a 1-way ANOVA
test followed by a Bonferroni post hoc test.
Cell-cycle analysis
Cell populations were trypsinized 48 hours after transfec-
tion with siRNAs and fixed in 70% ethanol overnight.
After a 1-hour incubation with RNase A at 37°C, the cells
were stained with 7AAD (eBioscience, San Diego, CA,
USA) before they were subjected to FACs analysis by
using a BD LSR II flow cytometer and analyzed with the
FACSDiva software. Statistical significance was determined
by using a one-way ANOVA test followed by a Bonferroni
post hoc test.
Results
Embryonic mammary epithelial cells are estrogen
receptor (ER)-, progesterone receptor (PR)-, and express
low levels////of Erbb2
Midgestation embryonic mammary bud epithelial (MBE)
cells are ER-, PR- and express low to moderate levels of
Erbb2 (Figure 1). Many MBE cells express high levels of
basal keratins (Krt5, Krt14), Egfr, and all express p63
(Figure 1). MBE cells exhibit marker profiles similar to
those used to describe the defining features of triple-nega-
tive and basal-like breast cancers and may use similar sig-
naling pathways and networks to underpin key biologic
properties of similar cell types found enriched within both
populations.
Subsets of the embryonic mammary signatures are
activated in Brca1-/- mouse tumors
We defined an embryonic mammary signature based on
expression profiles of genes found highly expressed
within midgestation (E12.5-stage) embryonic epithelium
compared with postnatal mammary epithelial cells
described in Additional file 2[10,13]. This signature is
distinct from the fetal mammary stem cell signature
recently defined by Spike et al. [30], which profiled sub-
populations of late-gestation (E18.5-stage) mammary
cells. Only 12 genes (1.4%) are shared between the two
embryonic signatures, which are both defined by
enriched expression in embryonic versus postnatal
mammary cell populations (see Additional file 2).
Next, we interrogated the embryonic-enriched mam-
mary epithelial signature expression in mammary
tumors that formed in mouse strains in which Brca1
had been deleted in either mammary epithelial luminal
progenitors (Blg-Cre Brca1f/f p53+/-) or in basal cells,
including basal stem cells (K14-Cre Brca1f/f p53+/-) [12],
to determine whether the embryonic signature is acti-
vated in a validated mouse model of triple-negative
breast cancer [31]. Small subsets of the embryonic
epithelial signature (123 of 689 genes (18%)) were acti-
vated in Brca1-/- mouse tumors when the embryonic
epithelial signature was used for hierarchic cluster analy-
sis (Figure 2A, B and Additional file 3).
Subsets of the embryonic mammary signatures are
activated in human breast cancers
Because only subsets of the embryonic mammary signa-
ture, and not the entire developmental program, appear
activated in mouse tumors, we sought to define the genes
shared between the embryonic signature and breast can-
cers across multiple datasets. We reasoned that this strat-
egy should result in the identification of embryonic
mammary genes consistently activated in breast cancers
that are not normally highly expressed by postnatal
mammary epithelial cells.
First, we compared the embryonic mammary epithelial
signature with those of human breast cancers by using
expression arrays from a dataset of 48 grade III ductal
carcinomas that were microdissected so that at least
90% of the sample contained tumor cells [16]. The
embryonic and tumor datasets profiled microdissected
tissues and reflected gene signatures present in highly
purified epithelial cell populations isolated from intact
tissues. One cluster of 30 embryonic mammary epithe-
lial genes, enriched for regulators of transcription and
actin cytoskeleton organization (see Additional File 4),
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was found to be activated predominantly in ER-negative
breast cancers, including all 13 basal-like tumors, all five
HER2-positive tumors, and four (13%) of 30 Luminal B
tumors (Figure 3A, B). Another small basal-like tumor-
associated subset was composed of genes encoding cell-
cycle and microtubule cytoskeleton components, sug-
gesting significant overlap with proliferation signatures,
a general hallmark of poor-prognosis breast cancers [32]
(see Additional file 4). The embryonic mammary epithe-
lium displays a relatively low proliferation index at
E12.5, but Ki67+ epithelial cells can be detected at this
stage (Figure 3C). Three other subsets of the embryonic
mammary epithelial signature are activated in many
non-basal-like tumor types (Figure 3B). One cluster acti-
vated predominantly in luminal tumors and repressed in
most basal-like tumors consists of genes regulating neu-
ron-projection development (Additional file 4). Two
other clusters are activated in some luminal and HER2+
tumors and are enriched for genes involved in embryo-
nic appendage morphogenesis, ossification, regionaliza-
tion, negative regulation of macromolecule synthesis,
and wound response (Additional file 4). The stability of
the gene clusters was assessed with pvClust (see Addi-
tional file 5). Of 57 genes activated in basal-like breast
cancers, 55 are found in one of the two major clusters,
which have robustness indices larger than 95%. Network
analysis suggests complex genetic regulatory potential,
and interacting associations exist between the proteins
encoded by embryonic genes found activated and
repressed in breast cancers (Figure 3D).
We also compared the embryonic mammary epithelial
signature with two additional breast cancer datasets, the
UNC337 dataset [17,33] and NKI295 dataset [15].
Distinct subsets of the embryonic mammary epithelial
signature were shown to be activated in breast cancers;
many were similar to those observed in the Natrajan
dataset (see Additional files 6, 7, and 8). Five genes are
found activated in the mouse Brca1-/- tumor dataset and
the three breast cancer datasets, predominantly in basal-
like cancers; statistical analysis indicated significant
enrichment of these genes (see Additional file 9). These
included two transcription factors, Bcl11a and Sox11,
and three other genes: B3gnt5, Ptdss1, and Tpx2. Fifty-
seven genes activated in at least two of four tumor data-
sets displayed enrichment of cell-cycle components
(Additional file 3). When 18 proliferation/cell-cycle-asso-
ciated genes (from signatures described [21]) were
removed, 39 remaining genes showed enrichment
for embryonic morphogenesis, suggesting that tumor-
associated genes mediate proliferation and processes
associated with embryonic development in basal-like can-
cers (Additional file 9). Fifty genes found activated predo-
minantly in non-basal-like types of breast cancers were
enriched for neuronal projection/differentiation and ossi-
fication, suggesting potential links to regulation of cellu-
lar processes regulating bone and nerve development in
other breast cancer subtypes (Additional file 10).
Many embryonic mammary signature components,
including ASPM, CDCA2, and KIF20A, are highly corre-
lated with established proliferation genes, such as KIF23
Figure 1 Embryonic mammary bud epithelial cells share key marker profiles with Brca1-/- and basal-like breast cancers. Many E12.5-
stage embryonic mammary bud epithelial cells display a triple-negative profile. Immunofluorescence (IF) with ERa shows stain throughout the
mammary mesenchymal tissue and no epithelial stain. IF with PR shows no staining of either mammary epithelial or mesenchymal cells. Control
tissue shows staining in some luminal mammary epithelial cells in postnatal tissue. Erbb2 is expressed at low to moderate levels by some
embryonic mammary epithelial cells, whereas other cells do not stain. Krt5 and Krt14 are highly expressed by many, but not all, embryonic
mammary epithelial cells. All embryonic mammary epithelial cells express p63; many express low to moderate levels of Egfr. Scale bar, 50 μm.
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Figure 2 Subsets of the embryonic mammary epithelial signature are activated in Brca1-/- mouse tumors. (A) Unsupervised hierarchic
clustering of embryonic epithelial signature expression in Brca1-/- mouse mammary tumor dataset. (B) Five clusters of Brca1-/- tumor-associated
embryonic genes and functional annotation. EMB, embryonic mammary cells; POST, postnatal mammary epithelial cells; F, mammary fibroblasts
[10]. TUMOURS are Brca1-/- mammary tumors from [12].
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Figure 3 Subsets of the embryonic epithelial mammary signature are activated in microdissected human breast cancers. (A)
Unsupervised hierarchic clustering of embryonic epithelial signature expressed in Natrajan tumor dataset. Breast cancer subtypes were defined
by the research version of PAM50 classification [18]. (B) Two subsets of embryonic genes from embryonic signature activated in basal-like breast
cancers and three subsets found repressed in basal-like breast cancers and activated in luminal tumors and their functional annotation. (C)
Proliferating cells are observed in the embryonic mammary bud epithelium with Ki67 stain. (D) Network of embryonic genes found activated
and repressed in basal-like breast cancers in Natrajan data set. (E) Box plots showing the average expression levels of the 37 embryonic genes in
the breast cancer subtypes classified by using PAM50 SSP on the NKI295 dataset. (F) Kaplan-Meier analysis shows significantly reduced distant
metastasis-free survival in patients with tumors with activation of embryonic mammary signature in the van de Vijver dataset [15] (c2 P value =
0.0028; log-rank P value = 0.0044).
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(58%) and TPX2 (69%) in the Natrajan dataset and with
TOP2A (39%), MKI67 (36%), and Ki67 protein expres-
sion (28%) in the Ghazoui et al. dataset [23] (Additional
file 10). We defined a 37-gene nonproliferative embryo-
nic mammary signature by excluding two genes found
present within two additional published proliferation
signatures [22,23] (see Additional file 11). When used in
hierarchic cluster analysis, this gene list resulted in
robust clustering of basal-like and non-basal-like cancers
in the Natrajan dataset. In addition, in the UNC337 and
NKI295 datasets, stable basal-like clusters were observed
(see Additional file 12). Different single-sample predic-
tors (SSPs) were used to classify the breast cancer sub-
types in the original publications. Given the differences in
the classification of breast cancers into the molecular sub-
types by means of SSPs [18,34], we retrieved the research
version of the PAM50 classification for the Natrajan data-
set [16] and NKI295 dataset [15] from [18] and PAM50
classification of the UNC337 dataset from [17]. Expression
levels of the embryonic gene signature were shown to be
highest in basal-like breast cancers compared with the
other breast cancer subtypes (Figure 3E). Enrichment for
the 37-gene nonproliferative embryonic signature was cor-
related with reduced-distance metastasis-free survival, lar-
ger tumor size, and the 70-gene signature used for
prognostication of breast cancer patients [15,19] in the
NKI295 dataset (Figure 3F; Additional file 13).
Given that many cancer cells undergo some degree of
epithelial-mesenchymal transition (EMT), we also defined
an embryonic mammary mesenchymal signature based on
expression profiles of genes found highly expressed within
embryonic mammary mesenchymal tissue compared with
postnatal mammary cells (see Additional file 14). We
found that a large percentage (62%) of the mesenchymal
genes are components of the embryonic mammary epithe-
lial signature, consistent with these epithelial cells under-
going morphogenesis and harboring some inherent
mesenchymal-like traits. Of the overlapping mesenchymal
genes, 25 were found in the 37-gene tumor-associated
embryonic epithelial signature, and could be considered
candidate regulators of EMT in breast cancers (see Addi-
tional file 15).
We next defined a tumor-associated mesenchymal sig-
nature. We used the criterion of genes found to be acti-
vated in basal-like cancers of at least two of four datasets,
and we removed genes that overlapped with the epithelial
signature. The final embryonic mesenchymal signature
would represent transcriptomic features unique to the
embryonic stroma. Several of these strictly mesenchymal
signature components (TGFBI, TWIST2, ZEB2) have
established links to EMT [35-37]. Enrichment for the 172-
gene mammary mesenchymal signature was correlated
with large tumor size and the 70-gene prognostic signa-
ture [15,19] in the NKI295 dataset (Additional file 15).
No significant association with overall survival was
observed in patients whose breast cancers showed activa-
tion of the embryonic mesenchymal signature (see Addi-
tional file 16).
BCL11A, SOX11, and TPX2 showed consistent upregula-
tion at an average of twofold or greater in ER- breast can-
cers across datasets (Figure 4A, B; Additional file 17)
[16,38-43]. SOX11 and TPX2 showed consistent upregula-
tion of twofold or greater in PR- breast cancers across
datasets (Figure 4C; Additional file 17) [16,39,41-46].
SOX11 levels were consistently twofold higher in HER2+
versus HER2- samples across datasets [16,40,42,47-49]
(Figure 4D and Additional file 18). SOX11 levels were
higher in basal-like and HER2+ breast cancers compared
with other subtypes (Figure 5E). BCL11A levels were con-
sistently higher in basal-like breast cancers compared with
other subtypes (Figure 4E). Both SOX11 and TPX2 showed
a trend of increased expression levels with increasing
tumor grade, whereas BCL11A did not (Figure 4F; Addi-
tional file 19). B3GNT5 levels tended to be higher in both
ER-negative and PR-negative tumors. No significant asso-
ciation of PTDSS1 with ER- , PR-, HER2- status, or histolo-
gic grade was found.
Several of the 52 genes found highly expressed in at least
two tumor datasets showed consistent trends in expres-
sion within tumor subtypes. UCHL1 is generally found
expressed at higher levels in basal-like tumors than the
other breast cancer subtypes (Figure 4E). Many cell-cycle-
associated genes (ASPM, CENPE, FAM60A, TPX2,
TRIP13, KIF11, KIF20A) were expressed at the highest
levels in basal-like tumors followed by HER2+, LumB,
Normal, and LumA (Figure 4E). Similar trends for the
cell-cycle-associated genes (ASPM, CENPE, TPX2,
TRIP13, KIF11, KIF20A) were observed with their distribu-
tion in different-grade tumors, with higher expression
levels observed as tumor grade increased (Figure 4F).
Patients with breast cancers expressing higher levels of
SOX11 showed worse overall survival than did those with
tumors expressing lower levels (Figure 4G). A trend exists
for reduced distant metastasis-free survival in patients
with breast cancers expressing higher levels of SOX11, but
is not statistically significant.
Tumor-associated embryonic mammary transcriptional
regulators are expressed in invasive Brca1-/- mammary
tumor cells
We analyzed expression of four embryonic mammary sig-
nature components that encode transcription factors in
normal mammary tissues and tumors. Bcl11a and Sox11
were expressed at approximately 20-fold and 100-fold
greater levels, respectively, in the embryonic mammary
epithelium when compared with postnatal mammary
epithelial cell (MEC) populations when assayed with qRT-
PCR (Figure 5A). Expression was also detected in RNA
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Figure 4 Core tumor-associated embryonic mammary genes associate significantly with key clinical parameters in breast cancers. (A)
Expression levels of core network activated across independent tumor datasets in ER+ versus ER- breast cancers. Red indicates expression levels
upregulated in ER- versus ER+ tumors; green indicates expression levels up in ER+ versus ER- tumors. (B) Five genes (ASPM, BCL11A, SOX11, TPX2,
and UCHL1) from the core network in Figure 5A show at least a twofold increase in expression levels in ER- versus ER+ breast cancers in seven
datasets [16,38-43]. (C) Five genes (ASPM, BCL11A, SOX11, TPX2, and UCHL1) from the core network shown in Figure 5A show at least a twofold
increase in expression levels in PR- versus PR+ breast cancers in eight datasets [16,39,41-46]. (D) Expression levels of core network activated
across six independent tumor datasets [16,40,42,47-49] in HER2- versus HER+ breast cancers. Red, expression levels upregulated in HER2- versus
HER2+ tumors; green, expression levels upregulated in HER2+ versus HER2- tumors. (E) Significance analysis of microarray (SAM) analysis of ASPM,
BCL11A, SOX11, UCHL1, and TPX2 expression according to tumor subtype, as defined by PAM50 [17], in breast cancers in the Lu dataset [40]. (F)
SAM analysis of ASPM, SOX11, and TPX2 expression according to grade in breast cancers in Miller dataset [41]. (G) Kaplan-Meier analysis shows
significantly reduced overall survival in the high SOX11 as compared with the low-SOX11 subgroup in the van de Vijver dataset [15] (c2 P value =
0.004; log-rank P value = 0.002133).
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Figure 5 Embryonic mammary transcription factors are highly expressed in some Brca1-/- mammary tumor cells. (A) qRT-PCR data
confirming embryonic-enriched expression of several basal-like tumor-associated transcription factors when compared with postnatal MEC
subpopulations (described in [10] and [13]). MP, mammary primordium; MBE, E12.5-stage mammary bud epithelium; MM, E12.5-stage mammary
mesenchyme; FB, fibroblast; ER-, luminal estrogen receptor negative; ER+, luminal estrogen-receptor positive; MYO, myoepithelial. (B) IHC showing
cell types expressing embryonic mammary marker, Sox11 (guinea-pig antiserum) within embryonic mammary primordium. (C) IHC showing low
level of Sox11 expression (guinea-pig antiserum) within 10-week-old postnatal mammary gland. (D-G) IHC showing Sox11 expression (guinea-pig
antiserum) in some, but not all, Brca1-/- tumors. Scale bar, 50 μm.
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isolated from Brca1-/- mouse mammary tumors: Bcl11a
was detected in seven of eight tumors, and Sox11 was
detected in two of eight tumors (see Additional file 20).
Grhl3 and Prox1 were expressed at 10-fold or more in the
embryonic mammary epithelium when compared with
postnatal MEC expression levels (Figure 5A) and were
expressed in some Brca1-/- tumors when profiled by qRT-
PCR (Additional file 20). Sox11 expression is predomi-
nantly observed in epidermal cells of the E12.5-stage
mammary bud (Figure 5B). Weak expression of Sox11 is
detected in postnatal MECs (Figure 5C). Nuclear Sox11
expression is observed in two of eight Brca1-/- tumors,
with highest levels of expression observed at the tumor-
invasion front adjacent to normal tissue (Figure 5D
through 5G). We conclude that several signature compo-
nents identified in our cancer dataset analysis are highly
embryonic enriched, expressed at sites of active tissue
remodeling in vivo during embryonic mammary develop-
ment and in many Brca1-/- mammary tumors.
SOX11 knockdown and overexpression in breast
cancer cells
We carried out loss-of-function assays to study further
the role of SOX11 in BT474 and BT549 invasive breast
cancer cells, which express relatively high (BT474) and
low levels (BT549) of SOX11 (see Additional file 21).
The results indicated that SOX11 knockdown signifi-
cantly impaired the viability and proliferation of both
cell types (Figure 6A-C and Additional file 21). BT549
cells transiently transfected with pCMV6-AC-SOX11-
GFP exhibited higher proliferation rates than did BT549
cells transiently transfected with a control GFP-expres-
sing plasmid (Additional file 21). SOX11 knockdown in
BT474 cells increased levels of cleaved caspase-3, a mar-
ker for apoptosis (Figure 6D). A significant reduction in
cells in G2/M phase was observed in cells transfected
with both the SOX11 SMARTpool and siRNA16, but
not with the siRNA15, which exhibits the largest change
in cell viability and largest increase in cleaved caspase-3
levels on SOX11 knockdown (Figure 6B through 6E).
Discussion
Embryonic mammary epithelium represents the least dif-
ferentiated mammary cells. Tumor-associated embryonic
mammary epithelial gene activation may therefore reflect
tumors containing a large proportion of less-differen-
tiated cells. Differentiation status, as defined by histologic
grade, is a clinically relevant aspect of breast tumors [50].
Undifferentiated tumors generally have a much worse
prognosis than do more-differentiated tumors [50]. A
small component of the embryonic-specific mammary
signature appears activated in mouse Brca1-/- tumors and
in approximately 80% of human basal-like breast cancers
in the datasets we examined. It is unclear whether they
express these programs for the same reasons or if their
expression in basal-like/triple-negative breast cancers is
due to genetic aberrations they harbor.
Many of the most common breast cancer driver muta-
tions, which confer survival advantage to breast cancer
cells and are implicated in causing cancers to form, are
found in genes that are also highly expressed by prenatal
breast cells. We have established this by comparing gene-
expression profiles of embryonic mammary tissues [1]
with recent mutational analyses obtained through deep
sequencing of breast cancers [2]. Aspects of embryonic
genetic programs with relevance to cancer have also been
suggested because “embryonic stem cell-like” (ESC) sig-
natures are found activated in many cancers, including
aggressive breast cancers [21]. However, most of these
signatures show a very strong correlation with levels of
proliferation-related genes [32,51,52]. Although we
observe correlation with proliferation for embryonic
mammary signature components after removing prolif-
eration-associated genes, we still observed clustering into
basal-like and non-basal breast cancers, suggesting that
the embryonic gene activation is also mediating other
cellular processes.
Four transcription factors (Bcl11a, Grhl3, Prox1, Sox11)
activated in Brca1-/- mouse tumors and basal-like human
breast cancers across multiple datasets were chosen for
validation studies, and all were confirmed to be embryo-
nic-enriched and highly expressed by some tumors. All
four genes have links to progenitor-cell regulation.
GRHL3 collaborates with Trithorax group members to
activate the epidermal progenitor differentiation program
[53]. Prox1 has been identified as a suppressor of hema-
topoietic stem cell activity [54], primary mediator of lym-
phangiogenesis [55], and promotes maintenance of
intermediate neural progenitors during adult neurogen-
esis [56]. BCL11A is expressed in lymphohematopoietic
cells, controls the development of B- and T-lymphocytes,
and is a common site of retroviral integration in myeloid
leukemia [57,58]. Two somatic mutations in BCL11A
have been reported in breast cancer [59]. Sox11, a high-
mobility-group transcription factor, has a widespread
role for in tissue remodeling in multiple organs [60] and
regulates neurogenesis [61,62]. Activated SOX11 expres-
sion has been described in Wilms tumor [63], a classic
example of an embryonic tumor, often characterized by
retention of embryonic cellular structures within the
tumor-bearing kidney [63]. SOX11 plays pivotal roles in
lymphoblastic neoplasms, mantle cell lymphoma, and
Burkitt lymphoma [64]. Both BCL11A and SOX11 belong
to the top 20 transcriptional regulators that correlate
with the core ES signature found activated in aggressive
breast cancers [21].
Antibody staining found Sox11 highly expressed at the
invasion front in some Brca1-/- mammary tumors. SOX11
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Figure 6 Effects of SOX11 knockdown on cell proliferation and viability of breast cancer cells. (A) SOX11 expression levels in BT474 cells
transfected with either SOX11 or control siRNAs. SOX11 was detected with immunoblotting. (B) BT474 cell number, represented as measured by
absorbance by using PrestoBlue cell-viability reagent, after transfection with SOX11 or nontargeting siRNAs at daily intervals. Values represent
mean ± SEM for three different experiments. (C) Change in percentage of viable cells was assessed by using PrestoBlue cell-viability assay of
BT474 cells 72 hours after transfection with SOX11 siRNAs compared with control siRNA. Values represent mean ± SD for three different
experiments; *P < 0.001, compared with the control. (D) Caspase-3 and cleaved caspase-3 levels detected by immunoblotting of lysates of
adherent and floating BT474 cells transfected with either SOX11 or control siRNAs. (E) After transfection with either SOX11 or control siRNA,
adherent BT474 cells were collected and stained with 7AAD. Cell-cycle phase was determined with FACS analysis. Values represent mean ± SD
for four independent experiments. *P < 0.05; and **P < 0.01 compared with the control.
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has been identified as mesenchymal stem cell (MSC) char-
acteristic gene [65] and potential biomarker for early pro-
genitor human MSCs [66]. Knockdown of SOX11
suppressed the self-renewal capacity and differentiation
potential of multiple MSC lines [65] and MSCs isolated
from bone marrow aspirates [66]. In mice, Sox11 is
required for proliferation of the sympathetic ganglia dur-
ing early developmental stages [28]. We found that silen-
cing of SOX11 in breast cancer cells led to an increased
expression of the apoptotic marker, cleaved caspase-3.
SOX11-deficient cell populations that showed moderate
decreases in viability also exhibited moderate increases in
cleaved caspase-3 levels and decreased percentages of cells
in G2/M phase, whereas no change in the G2/M percen-
tage was observed in the least viable SOX11-deficient cell
population that displayed the highest increase in cleaved
caspase-3 levels. These results suggest that a more efficient
SOX11 knockdown could lead to more rapid apoptosis
when compared with cells with moderately reduced
SOX11 levels, which may possibly undergo prolonged cell-
cycle arrest before subsequent apoptosis. A number of stu-
dies have found that Sox11 is also required for survival of
neural cells and mesenchymal progenitor cells [67-69]. We
found that silencing of SOX11 in breast cancer cells
reduces cell survival and cell viability, and SOX11 overex-
pression leads to increased proliferation rates, suggesting
that SOX11 could have a similar function in regulation of
proliferation and survival in several types of cells. High
levels of SOX11 expression are associated with poor over-
all survival in breast cancer patients, but its function in
breast epithelial cells is not clear and remains to be further
investigated.
A study by Spike et al. [30], found evidence of molecu-
lar similarity of subpopulations of E18.5-stage mammary
cells to breast cancers. In that study [30], cells from
mammary primordia were separated into subpopulations
based on expression of cell-surface markers to enrich for
stem cells. The signature used in our study represents
the entire embryonic mammary epithelial organogenetic
program, because it is derived from gene-expression pro-
files of intact epithelial tissues. Lineage-tracing studies
have shown that embryonic mammary bud epithelial
cells labeled at midgestation (E12.5-stage) onward give
rise to both basal and luminal lineages [70,71]. Therefore,
our embryonic signature will include progenitor/stem
cells as well as other cells within their native microenvir-
onment. Tumors are composed of multiple cell types,
and some behavioral features are similar to organotypic
growth [72]. Distinctions in both the developmental
stages (E12.5 versus E18.5 stage) and biologic features of
the cell populations (tissues versus fractionated subpopu-
lations of dissociated cells) that were profiled in the two
studies are likely to account for the limited overlap
between the signatures. Only one gene (Bcl11a) from the
37-gene signature defined here is shared with one of the
tumor-associated subsets defined in the study by Spike
et al. [30].
Our results reveal a small number of genes associated
with embryonic mammary development and human
basal-like breast cancers. Although this lends support to
the notion that reactivation of components of the mam-
mary organogenetic program has detrimental effects in
postnatal MECs, our results suggest that only a small
fraction of the early (E12.5-stage) embryonic mammary
developmental program is highly expressed or reactivated
in breast tumors. A substantial component of the tumor-
associated embryonic epithelial signature comprises
genes regulating cell proliferation. This is somewhat
unexpected, because the embryonic mammary epithelium
exhibits a low proliferation index [73,74]. However, sev-
eral cell-cycle-associated genes are associated with its
signature, and may regulate proliferation of particular
progenitor cells as the immature mammary cell popula-
tion expands. One tumor-associated embryonic gene,
ASPM, regulates symmetric versus asymmetric cell divi-
sions in progenitor cells and also regulates WNT signal-
ing in the developing brain [75,76].
We documented activation of embryonic genes in
mammary tumors from mice in which Brca1-/- was inac-
tivated in either luminal progenitor cells or basal cells
[12]. These observations suggest that it is loss of Brca1
and not the cell of origin that may be dictating the
embryonic gene signature expression. These Brca1-/-
mice were Tp53+/-; hence, it is possible that loss of p53
function is also contributing to the observed embryonic
gene activation in the Brca1-/- tumors. p53 has been
shown to regulate polarity of cell division in mammary
stem cells, and loss of p53 appears to promote symmetric
divisions of cancer stem cells, contributing to tumor
growth [77].
Conclusions
A limited subset of the early mammary developmental
program is likely to have a role in promoting tumorigen-
esis, but its association with some human breast tumors
and patient outcome warrants further investigation. We
have identified a small network of embryonic genes that
are found highly expressed in a subset of basal-like breast
cancers and are candidate regulators of cancer cells.
These results provide support for the notion that overac-
tivation of small particular aspects of the embryonic
mammary genetic program could play a key role in regu-
lating detrimental cellular behaviour, such as tissue
remodeling, invasive growth, and/or progenitor cell
expansion. Expression of particular embryonic mammary
markers within tumor cells may reflect reactivation of
genetic programs that influence the behavior of imma-
ture cell types present within the breast and may elicit
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cell behavior associated with embryonic cells, such as a
less-differentiated, highly plastic state. Tumor-associated
embryonic mammary markers may have value to be
exploited as they could represent a novel means to
describe and categorize the biologic state of tumor cell
populations for use in breast cancer classification as well
as potential drug targets.
Additional material
Additional file 1: Antibodies used for immunohistochemistry and
whole-mount immunofluorescence. (A) Table gives details of
antibodies used in this study. (B) Positive control for Sox11 (guinea-pig
antiserum) staining of E12.5-stage forebrain. (C) No primary antibody
control for Sox11 (guinea-pig antiserum) staining of E12.5-stage
mammary primordium. Scale bar, 50 μm.
Additional file 2: Embryonic mammary epithelial signature and
functional annotation clustering. Table of embryonic mammary
epithelial signature based on the expression profiles of genes found
highly expressed (10-fold or greater) within mammary bud epithelial cells
when compared with postnatal mammary epithelial cells and functional
annotation clustering of the embryonic mammary epithelial gene
signature. Genes shared by this signature and the “uniquely fetal
mammary stem cell” signature defined by Spike et al. [30] are indicated.
Additional file 3: Embryonic genes found activated in mouse
Brca1-/- tumors. Table shows embryonic genes found activated in
mouse Brca1-/- tumors and functional-annotation clustering. Functional-
analysis clustering lists the category of gene set (for example, CC, cellular
location; BP, biologic process; MF, molecular function); term (that is,
specific gene ontology (GO) with GO number); count (number of genes
enriching term); % (percentage of total of genes that belong to category
enriched by analyzed gene set); P value (that is, enrichment of gene set);
genes (list of genes enriching gene set by Affymetrix ID); Bonferroni;
Benjamini, and FDR (false discovery rate) for functional annotation
clustering of genes expressed in tumor-associated gene modules defined
by cluster analysis.
Additional file 4: Embryonic genes found activated and repressed
in basal-like, HER2+, or luminal breast cancer subtypes in Natrajan
data set. Functional-analysis clustering lists the category of gene set (CC,
cellular location; BP, biologic process; MF, molecular function); term
(specific gene ontology (GO) with GO number); count (number of genes
enriching term); % (percentage of total of genes that belong to category
enriched by analyzed gene set); P value (enrichment of gene set); genes
(list of genes enriching gene set by Affymetrix ID); Bonferroni; Benjamini,
and FDR (false discovery rate) for functional-annotation clustering of
genes expressed in tumor-associated gene modules defined by cluster
analysis.
Additional file 5: Cluster-stability analysis of the hierarchic
clustering of the embryonic mammary signature in breast cancer
datasets by using the R-package pvclust. Figure shows stability
analysis with Approximately Unbiased (AU) P value (shown in green)
larger than 95% highlighted by rectangles and strongly supported by
data. (A) Cluster-stability analysis of the hierarchic clustering of the
embryonic mammary signature in the Natrajan breast cancer samples. Of
the 57 basal-like genes, 55 are in the left cluster, and the two major
clusters are significantly different. (B) Cluster-stability analysis of the
hierarchic clustering of the embryonic mammary signature in the
UNC337 breast cancer samples. (C) Cluster-stability analysis of the
hierarchic clustering of the embryonic mammary signature in the NKI295
breast cancer samples.
Additional file 6: Similar embryonic epithelial mammary signature
subsets are activated across multiple human breast cancer datasets.
(A, B) Five embryonic gene clusters activated in UNC337 dataset by
using unsupervised hierarchic clustering and functional annotation.
Tumor subtypes were defined by PAM50, as described [17]. (C, D) Four
embryonic gene clusters activated in NKI295 dataset by using
unsupervised hierarchic clustering and functional annotation. Subtypes
were as defined by the research version of PAM50 classification [18]. The
70-gene prognosis signature was used to classify tumors as to whether
tumors are likely to predictive of a short interval to distant metastases
(poor) or not (good) [15,19].
Additional file 7: Embryonic genes found activated and repressed
in basal-like, HER2+, luminal or normal breast cancer subtypes in
UNC337 data set. Functional-analysis clustering lists the category of
gene set (CC, cellular location; BP, biologic process; MF, molecular
function); term (specific gene ontology (GO) with GO number); count
(number of genes enriching term); % (percentage of total of genes that
belong to category enriched by analyzed gene set); P value (enrichment
of gene set); genes (list of genes enriching gene set by Affymetrix ID);
Bonferroni; Benjamini, and FDR (false discovery rate) for functional
annotation clustering of genes expressed in tumor-associated gene
modules defined by cluster analysis.
Additional file 8: Embryonic genes found activated or repressed in
basal-like, HER2+, luminal, or normal breast cancer subtypes in
NKI295 data set. Functional-analysis clustering lists the category of gene
set (CC, cellular location; BP, biologic process; MF, molecular function);
term (specific gene ontology (GO) with GO number); count (number of
genes enriching term); % (percentage of total of genes that belong to
category enriched by analyzed gene set); P value (enrichment of gene
set); genes (list of genes enriching gene set by Affymetrix ID); Bonferroni;
Benjamini, and FDR (false discovery rate) for functional annotation
clustering of genes expressed in tumor-associated gene modules defined
by cluster analysis.
Additional file 9: Embryonic genes activated in mouse Brca1-/-
tumors and basal-like breast cancers, in at least two of four
datasets examined and their functional annotation and
hypergeometric statistical analysis.
Additional file 10: Embryonic genes activated in non-basal-like
breast cancer subtypes in at least two of three breast cancer
datasets examined and their functional annotation.
Additional file 11: Correlation tests of embryonic genes with
proliferation genes used to define nonproliferative embryonic
mammary gene signature with proliferation genes, t tests of
average expression of embryonic genes in tumor subtypes with
different SSPs and centroid analysis of nonproliferative gene
signature in NKI295 dataset. (A) Pearson correlation of KIF23 with
embryonic gene signature in Natrajan dataset. (B) Pearson correlation of
TPX2 with embryonic gene signature in Natrajan dataset. (C) Pearson
correlation of TOP2A with embryonic gene signature in FAIMos dataset.
(D) Pearson correlation of MKI67 with embryonic gene signature in
FAIMos dataset. (E) Spearman correlation of Ki67 protein expression with
embryonic gene signature in FAIMos dataset. (F) Nonproliferative
embryonic mammary gene signature.
Additional file 12: Cluster-stability analysis of the hierarchic
clustering of the embryonic mammary signature in breast cancer
datasets by using the R-package pvclust. (A) Cluster-stability analysis;
55 of the 57 basal-like genes are in the left cluster, and the two major
clusters are significantly different. (B) Cluster-stability analysis of the
hierarchic clustering of the nonproliferative embryonic mammary
signature in the UNC337 breast cancer samples. (C) Cluster-stability
analysis of the hierarchic clustering of the nonproliferative embryonic
mammary signature in the NKI295 breast cancer samples.
Additional file 13: The t tests of average expression of embryonic
genes in tumor subtypes by using different SSPs and centroid
analysis of nonproliferative gene signature. (A) Summary of array-
expression data for the 37-gene embryonic mammary epithelial signature
used to define centroids. (B) Median gene expression of 37 genes
comprising embryonic mammary epithelial gene signature. (C) Definition
of centroids for embryonic mammary epithelial signature. (D) Centroid
correlation with NKI295 dataset. (E) Multivariate Cox Proportional Hazard
Regression analysis.
Additional file 14: Embryonic mammary mesenchymal signature
and functional annotation clustering. Table of embryonic mammary
epithelial signature based on the expression profiles of genes found
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highly expressed (10-fold or greater) within mammary mesenchymal cells
when compared with postnatal mammary epithelial cells and functional
annotation-cluster analysis of the embryonic mammary mesenchymal
gene signature.
Additional file 15: Embryonic mesenchymal genes activated in
mouse Brca1-/- tumors and basal-like breast cancers. These are from
at least two of four datasets examined and Multivariate Cox Proportional
Hazard Regression analysis of 172-gene uniquely mesenchymal signature.
Additional file 16: Mesenchymal signature activation in breast
cancers. (A) Kaplan-Meier analysis shows a trend toward reduced overall
survival in patients with tumors with activation of embryonic
mesenchymal signature (172 genes) in the van de Vijver dataset [15] (c2
P value = 0.066, log-rank P value = 0.07368). (B) Box plots showing the
average expression levels of the mesenchymal 172-gene signature in the
breast cancer subtypes classified by using PAM50 SSP on the NKI295
dataset.
Additional file 17: Fold-change expression levels of core network
components activated across independent tumor datasets. The
average in ER- versus ER+ breast cancers; PR- versus PR+ breast cancers;
and HER2- versus HER+ breast cancers, including associated P values.
Additional file 18: Expression of core network of tumor-associated
embryonic genes in HER2+ versus HER2- breast cancers in six
datasets.
Additional file 19: Significance analysis of microarray analysis of the
expression of core network of tumor-associated embryonic genes
according to tumor grade and tumor subtype.
Additional file 20: Expression of embryonic genes in mammary
tissues and Brca1-/- tumors. (A) qRT-PCR analysis of four tumor-
associated transcription factors in Brca1-/- mouse mammary tumors. (B)
IHC showing SOX11 expression (Cell Marque MRQ-58) within embryonic
mammary primordium. (C) No primary antibody control for SOX11 (Cell
Marque MRQ-58). (D) IHC showing low level of SOX11 expression (Cell
Marque MRQ-58) within 10-week-old postnatal mammary gland. (E)
Positive control showing SOX11 expression (Cell Marque MRQ-58) in
E12.5-stage forebrain. (F) Control showing SOX11 expression (Cell
Marque MRQ-58) in E16.5-stage Sox11-/- spinal cord. (G through J) IHC
showing SOX11 expression (Cell Marque MRQ-58) in some, but not all,
Brca1-/- tumors. Scale bar, 50 μm.
Additional file 21: Effects of SOX11 knockdown on cell viability of
breast cancer cells. (A) qRT-PCR analysis of SOX11 levels in BT549 cells
transfected with either SOX11 SMARTpool or control siRNAs. (B) SOX11
expression in BT474 cells compared with BT549 cells by immunoblotting.
(C) Immunoblotting of lysates from cells transiently transfected with
either SOX4 or SOX11 expression vectors (Origene) show that SOX11
antibody (Epitomics) does not detect SOX4. SOX4 shares a high degree
of identity both in the HMG box domain and in the C-terminal region
and is of a similar molecular mass to SOX11 (60 versus 59 kDa), in
agreement with previously published data [78]. (D) BT549 cell number
represented as measured by PrestoBlue cell viability reagent after
transfection with SOX11 or nontargeting siRNAs at daily intervals. Values
represent means ± SD for three different experiments. (E) Change in
percentage of viable cells was assessed by using PrestoBlue cell-viability
assay of BT549 cells 72 hours after transfection with SOX11 siRNAs
compared with control siRNA. Values represent mean ± SD for three
different experiments. *P < 0.05, and ***P < 0.001 compared with the
control. (F). Absorbance of BT549 cells transfected with either SOX11-GFP
or control GFP-expressing plasmid was assessed by using PrestoBlue cell-
viability assay at daily intervals. Values represent mean ± SEM for three
independent experiments; *P < 0.05, compared with the control. The
transfection efficiency was about 24% for the SOX11-GFP-expressing
plasmid.
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